{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:19:51Z","timestamp":1774549191010,"version":"3.50.1"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The spread of extended-spectrum-\u03b2-lactamase (ESBL)-producing organisms, particularly those harboring the CTX-M-type enzymes, both in the hospital and in the community, is difficult to discontinue due to the successful mobilization and evolution of the genetic elements harboring ESBL genes and coresistance rates in these isolates. The activities of tigecycline against 285 non-clonally related isolates (172 from\n            <jats:italic>Escherichia coli<\/jats:italic>\n            , 84 from\n            <jats:italic>Klebsiella<\/jats:italic>\n            spp., 20 from\n            <jats:italic>Enterobacter<\/jats:italic>\n            spp., 5 from\n            <jats:italic>Salmonella<\/jats:italic>\n            spp., and 4 from\n            <jats:italic>Citrobacter<\/jats:italic>\n            spp.) expressing well-characterized ESBLs and recovered in our hospital and its community area of influence were comparatively assessed (CLSI microdilution). Susceptibility rates for meropenem, imipenem, tigecycline, amikacin, and piperacillin-tazobactam were 100%, 100%, 97.5%, 93.3%, and 93%, respectively. Tigecycline (mode MIC, 0.5 \u03bcg\/ml; MIC\n            <jats:sub>90<\/jats:sub>\n            , 1 \u03bcg\/ml) was 4- to 256-fold more active than doxycycline and minocycline (mode MIC range, 2 to 128 \u03bcg\/ml). CTX-Ms were the most frequent ESBLs (61.4%), 65.8% in community and 58.6% in nosocomial isolates. CTX-M-9 (22%), CTX-M-14 (15.8%), and CTX-M-10 (14%) were the most represented derivatives. SHV and TEM variants constituted 22.8% and 15.8% of the ESBLs, respectively. Overall coresistance rates were as follows: gentamicin, 27.4%; tobramycin, 27.4%; amikacin, 6.7%; and chloramphenicol, 29.1%. Sulfonamide (61.7%), trimethoprim (52.3%), streptomycin (50.5%), and ciprofloxacin (37.2%) resistance levels were significantly (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001) associated with CTX-M-9 producers. No tigecycline resistance was observed, although seven\n            <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n            isolates exhibited intermediate MICs (4 \u03bcg\/ml). Tigecycline, lacking cross-resistance with other compounds, could represent an opportunity to reduce the intensity of selection for ESBL-producing organisms derived from the use of other antimicrobial agents. However, this in vitro promise requires support from clinical studies.\n          <\/jats:p>","DOI":"10.1128\/aac.00155-06","type":"journal-article","created":{"date-parts":[[2006,7,26]],"date-time":"2006-07-26T18:17:58Z","timestamp":1153937878000},"page":"2695-2699","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":116,"title":["Antibiotic Coresistance in Extended-Spectrum-\u03b2-Lactamase-Producing\n            <i>Enterobacteriaceae<\/i>\n            and In Vitro Activity of Tigecycline"],"prefix":"10.1128","volume":"50","author":[{"given":"Mari\u0301a-Isabel","family":"Morosini","sequence":"first","affiliation":[{"name":"Servicio de Microbiologi\u0301a, Hospital Universitario Ramo\u0301n y Cajal, Madrid, Spain"}]},{"given":"Mari\u0301a","family":"Garci\u0301a-Castillo","sequence":"additional","affiliation":[{"name":"Servicio de Microbiologi\u0301a, Hospital Universitario Ramo\u0301n y Cajal, Madrid, Spain"}]},{"given":"Teresa M.","family":"Coque","sequence":"additional","affiliation":[{"name":"Servicio de Microbiologi\u0301a, Hospital Universitario Ramo\u0301n y Cajal, Madrid, Spain"}]},{"given":"Ara\u0301nzazu","family":"Valverde","sequence":"additional","affiliation":[{"name":"Servicio de Microbiologi\u0301a, Hospital Universitario Ramo\u0301n y Cajal, Madrid, Spain"}]},{"given":"A\u0302ngela","family":"Novais","sequence":"additional","affiliation":[{"name":"Servicio de Microbiologi\u0301a, Hospital Universitario Ramo\u0301n y Cajal, Madrid, Spain"}]},{"given":"Elena","family":"Loza","sequence":"additional","affiliation":[{"name":"Servicio de Microbiologi\u0301a, Hospital Universitario Ramo\u0301n y Cajal, Madrid, Spain"}]},{"given":"Fernando","family":"Baquero","sequence":"additional","affiliation":[{"name":"Servicio de Microbiologi\u0301a, Hospital Universitario Ramo\u0301n y Cajal, Madrid, Spain"}]},{"given":"Rafael","family":"Canto\u0301n","sequence":"additional","affiliation":[{"name":"Servicio de Microbiologi\u0301a, Hospital Universitario Ramo\u0301n y Cajal, Madrid, Spain"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00269-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.1-14.2004"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.11.006"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/431673"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki175"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_3_2_8_2","unstructured":"Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests 9th ed. Approved standard M2-A9. Clinical Laboratory and Standards Institute Wayne Pa."},{"key":"e_1_3_2_9_2","unstructured":"Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically 7th ed. Approved standard M7-A7. Clinical Laboratory and Standards Institute Wayne Pa."},{"key":"e_1_3_2_10_2","unstructured":"Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. CLSI document M100-S16. Clinical and Laboratory Standards Institute Wayne Pa."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.500-510.2002"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1636-1638.2005"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.04.013"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.2122-2125.2005"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.06.001"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.2004.tb09534.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki291"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki239"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1823-1829.2005"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1865-1871.2005"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.400-404.2003"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi0506066"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.11.006"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki245"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1567-1571.2005"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki166"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.3.1089-1094.2004"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1017-1022.2005"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.2137-2139.2005"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.10.4769-4775.2004"},{"key":"e_1_3_2_32_2","unstructured":"Wyeth Pharmaceutics. 2005. Tygacil (tigecycline) for injection [package insert]. Wyeth Pharmaceuticals Inc. Philadelphia Pa."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.4.1.9"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00155-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00155-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:15:26Z","timestamp":1645470926000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00155-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1128\/AAC.00155-06"],"URL":"https:\/\/doi.org\/10.1128\/aac.00155-06","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"2006-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-06-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}